Table 1.

Characteristics of patients and CFU-MEG growth, with or without imetelstat

Subject no.	Sex	Age, y*	Disease duration, d	Mutational status	Treatment*	Hb, g/dL*	Lc, × 109/L*	Plt, × 109/L*	CFU-MEG ± SD (n = 2)
									Spontaneous growth	Imetelstat, μM			Mismatch control oligo (10 μM)
										0.1	1	10
ET patients
1	F	47	521	JAK2 V617F	None	14.1	11.3	700	18 ± 1.77	26 ± 1.06	22 ± 0.71	8 ± 0.35	28 ± 1.77
2	F	65	440	JAK2 V617F	HU, aspirin	11.7	3.6	342	33 ± 4.95	35 ± 1.41	16 ± 1.41	13 ± 1.41	37 ± 0.0
3	F	84	767	JAK2 V617F	Radiophosphor, aspirin	11.6	8	182	25 ± 2.12	26 ± 1.41	24 ± 2.83	11 ± 1.41	22 ± 1.41
4	F	37	2669	JAK2 V617F	Aspirin	14.7	13.3	994	100 ± 26.9	77 ± NA (n = 1)	37 ± NA (n = 1)	14 ± NA (n = 1)	102 ± NA (n = 1)
5	F	64	1132	CALR type 2	Interferon-α2a	11.8	2.2	250	21 ± 0.71	29 ± 7.07	17 ± 4.95		21 ± 6.36
6	M	74	1820	Triple negative	HU, aspirin	12.6	6.6	564	58 ± 10.2	68 ± 2.83	30 ± NA (n = 1)	26 ± 14.85	49 ± 4.95
7	F	79	862	CALR type 1	HU, aspirin	12.3	13.7	700	24 ± NA (n = 1)	8 ± 1.41	7 ± 0.0	3 ± 0.71	22 ± NA (n = 1)
8	M	66	14	JAK2 V617F	HU, aspirin	15.9	10.7	834	37 ± NA (n = 1)	52 ± 3.54	18 ± 4.95	5 ± NA (n = 1)	27 ± NA (n = 1)
9	M	58	3716	JAK2 V617F	HU, aspirin	15.5	5.5	364	10 ± 4.24	8 ± 1.41	4 ± 0.71	4 ± NA (n = 1)	11 ± 5.66
10	M	51	1	JAK2 V617F	HU, aspirin	16.5	6.9	677	37 ± NA (n = 1)	42 ± 0.0	35 ± 12.73	18 ± 2.83	33 ± 7.07

									Cytokine-driven growth
HIs
1	M	51	NA	NA	NA	17.2	5	127	28 ± 4.24	26 ± 2.83	27 ± 1.41	24 ± 2.83	36 ± 4.95
2	M	50	NA	NA	NA	15.5	6.6	175	11 ± 2.3	12 ± 6.36	12 ± 5.66	19 ± 1.41	12 ± 1.41
3	M	40	NA	NA	NA	14.8	4.7	125	18 ± 0.0	20 ± 8.49	22 ± 3.54	14 ± 2.83	15 ± 2.83

F, female; Hb, hemoglobin; HU, hydroxyurea; Lc, leukocytes; M, male; NA, not applicable; Plt, platelets; SD, standard deviation.

^*At time of progenitor cell assay.